Angiotensin II-induced venoconstriction involves both AT1 and AT2 receptors and is counterbalanced by nitric oxide

被引:16
作者
Fernandes, L [1 ]
Loiola, RA [1 ]
Tostes, RCA [1 ]
Nigro, D [1 ]
Fortes, ZB [1 ]
de Carvalho, MHC [1 ]
机构
[1] Univ Sao Paulo, Dept Pharmacol, Inst Biomed Sci, BR-0550900 Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
angiotensin; veins; venules; nitric oxide; receptors;
D O I
10.1016/j.peptides.2005.05.025
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The venoconstrictor effect of Angiotensin II (Ang II) was investigated in the rat mesenteric venules and portal vein. Mesenteric venules were perfused at a constant rate and reactivity to Ang II (0.1 nmol) was evaluated as changes in the perfusion pressure. Rings of portal vein were mounted in organ baths and curves to Ang II (0.1-100 nmol/L) were generated. In venules, Ang II-contraction (10.6 +/- 1.1 mmHg) was abolished by losartan (0.9 +/- 0.3 mmHg*), reduced by PD 123,319 (5.8 +/- 0.9 mmHg*), increased by L-NAME (16.5 +/- 1.8 mmHg*) and not altered by indomethacin. In portal veins, curves to Ang II (-log EC50: 8.9 +/- 0.1 mol/L) were shifted to the right by losartan (-log EC50: 7.5 +/- 0.1 mol/L*) and by PD 123,319 (-log EC50: 8.0 +/- 0.1 mol/L*). L-NAME increased the maximal response to Ang II (E-max: 0.91 +/- 0.1 g versus 1.62 +/- 0.3 g*) and indomethacin had no effect. In conclusion, Ang II induces venoconstriction by activating AT1 and AT2 receptors. Data obtained with L-NAME provide evidence that the basal nitric oxide release from the endothelium of the venous system can modulate the Ang II-induced venoconstriction. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:2458 / 2463
页数:6
相关论文
共 35 条
[1]  
CAMPOS AH, 1994, J PHARMACOL EXP THER, V268, P902
[2]  
de Gasparo M, 2000, PHARMACOL REV, V52, P415
[3]   STUDIES ON RELATIONSHIP BETWEEN FLOW RESISTANCE, CAPILLARY FILTRATION COEFFICIENT AND REGIONAL BLOOD VOLUME IN INTESTINE OF CAT [J].
FOLKOW, B ;
LUNDGREN, O ;
WALLENTINE, I .
ACTA PHYSIOLOGICA SCANDINAVICA, 1963, 57 (03) :270-&
[4]   Losartan potassium - A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension [J].
Goa, KL ;
Wagstaff, AJ .
DRUGS, 1996, 51 (05) :820-845
[5]  
KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543
[6]   Nonendothelial source of nitric oxide in arterioles but not in venules - Alternative source revealed in vivo by diaminofluorescein microfluorography [J].
Kashiwagi, S ;
Kajimura, M ;
Yoshimura, Y ;
Suematsu, M .
CIRCULATION RESEARCH, 2002, 91 (12) :E55-E64
[7]  
Kenakin T., 1997, MOL PHARM SHORT COUR
[8]   EVIDENCE THAT THE APPARENT COMPLEXITY OF RECEPTOR ANTAGONISM BY ANGIOTENSIN-II ANALOGS IS DUE TO A REVERSIBLE AND SYNOPTIC ACTION [J].
LIU, YJ ;
SHANKLEY, NP ;
WELSH, NJ ;
BLACK, JW .
BRITISH JOURNAL OF PHARMACOLOGY, 1992, 106 (02) :233-241
[9]   VASCULAR SELECTIVITY OF FELODIPINE [J].
LJUNG, B .
DRUGS, 1985, 29 :46-58
[10]  
LJUNG B, 1970, ACTA PHYSIOL SCAND, P33